CDKN1C is a tight-binding inhibitor of several G1 cyclin/CDK complexes, including cyclin E-CDK2, cyclin D2-CDK4, cyclin A-CDK2 and the mitotic cyclin B-CDC2. It functions as a negative regulator of cell proliferation and may help maintain the non-proliferative state throughout life. Mutations in CDKN1C result in Beckwith-Wiedemann syndrome, characterized by early-onset tumorigenesis, and are associated with some sporadic cancers. Loss of functional CDKN1C is also correlated with IMAGe syndrome (or Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal hypoplasia congenita, and Genital anomalies). CDKN1C antibodies are useful for identifying hydatidiform moles, which lack expression of the protein. In immunohistochemistry of normal tissue, CDKN1C has nuclear positivity in the adrenal gland, glomeruli in the kidney, placenta and a few other tissues. References: Nature Genetics. 44 (7): 737–8, PMID: 22735584; Human Genetics. 100 (5–6): 681–3, PMID: 9341892; The UniProt Consortium. Nucleic Acids Res. 47: D506-515 (2019); Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45, PMID:26553804; American Journal of Clinical Pathology. 129 (5): 749–755, PMID: 18426735;